FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Brii Biosciences Limited Stock AnalysisComprehensive stock analysis for Brii Biosciences Limited (BRIBF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisBRIBF
BRIBF
Brii Biosciences Limited
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
BRIBF
Home🔹Stocks🔹Brii Biosciences Limited

Brii Biosciences Limited

BRIBF•OTC

Brii Biosciences Limited

BRIBF•OTC
Market cap
$135.65M
Sentiment

Your view on BRIBF

Mkt Cap
$135.65M
Sentiment
Your view
BRIBF
Brii Biosciences Limited
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
BRIBF
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Brii Biosciences Limited

Industry
Biotechnology
Sector
Healthcare
CEO
Zhi Hong
Headquarters
Building 7, Beijing, CN
Industry
Biotechnology
Sector
Healthcare
CEO
Zhi Hong
Headquarters
Building 7, Beijing, CN
Description

Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News